Overcoming Resistance In Cancer With Chemistry The Bio Report podcast

Artwork

Biotech Science Natural Sciences Business Biology Levine Media Group Gene Therapy

Innhold levert av Levine Media Group. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Levine Media Group eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

The Bio Report « »
Overcoming Resistance in Cancer with Chemistry

2M ago 30:01

Del

MP3•Episoder hjem

Innhold levert av Levine Media Group. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Levine Media Group eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Kinase inhibitors have given rise to an era of precision medicine for the treatment of cancer, but the ability of cancer cells to mutate enables tumors to develop resistance to existing therapies. Nuvalent is developing therapies that both target the original tumor as well tumors with emergent resistance. We spoke to James Porter, CEO of Nuvalent, about how it designs drugs that address the challenges of both kinase resistance and selectivity, its pipeline in development, and why it’s critical that its experimental therapy for non-small cell lung cancer can penetrate the brain.

… continue reading

517 episoder

#Biotech #Science #Natural Sciences #Business #Biology #Levine Media Group #Gene Therapy

Artwork

Overcoming Resistance in Cancer with Chemistry

358 subscribers

published 2M ago

Del

MP3•Episoder hjem

Innhold levert av Levine Media Group. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Levine Media Group eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Kinase inhibitors have given rise to an era of precision medicine for the treatment of cancer, but the ability of cancer cells to mutate enables tumors to develop resistance to existing therapies. Nuvalent is developing therapies that both target the original tumor as well tumors with emergent resistance. We spoke to James Porter, CEO of Nuvalent, about how it designs drugs that address the challenges of both kinase resistance and selectivity, its pipeline in development, and why it’s critical that its experimental therapy for non-small cell lung cancer can penetrate the brain.

… continue reading

517 episoder

#Biotech #Science #Natural Sciences #Business #Biology #Levine Media Group #Gene Therapy

Toate episoadele

×

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

Lytt til 500+ tema